Zacks Investment Research on MSN
RVTY unveils Signals BioDesign for faster molecular cloning & R&D data
Revvity, Inc. RVTY announced the launch of Signals BioDesign, a cloud-based molecular cloning platform, under its Revvity ...
Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA ...
Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
A new integrated service allows Tamarind Bio’s platform users to validate affinity and specificity of computationally designed binder predictions through A-Alpha Bio’s AlphaSeq platform.
Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...
For many years, the landscape of data center innovation has been dominated by solid-state electronics. The relentless pursuit of faster chips, denser racks and larger facilities has been the mantra ...
AI systems are only as fair and safe as the data they’re built on. While conversations about AI ethics often focus on model architecture, algorithmic transparency or deployment oversight, fairness and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results